Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: jake burns who wrote (5990)	1/27/1999 2:11:00 AM
From: Joe E.	Respond to of 6136

It looks like they ( AGPH management) get to keep their independence, which was probably a major factor for management and science staff. I have been thinking for some time that AGPH was very tax inefficient in their R+D spending, and this merger whould fix that problem. So AGPH trades a little stock price for independence, IMHO. I think they could easily have gotten another $5 or so, but they didn't. A smart buy by WLA. Take your chips and move on, or take the WLA stock and see what happens. Either way it looks like a done deal to me. There are plenty of other biotechs out there.